Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 820 results for "daiichi sankyo company"

Sun Pharma, Daiichi terminate transaction pacts
Money Control

Amgen and Daiichi Sankyo to Commercialize Biosimilars in Japan

Amgen and Daiichi Sankyo Company have announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and ... CPhI.cn, 1 week ago
[x]  

10 images for daiichi sankyo company

Nasdaq, 2 weeks ago
Nasdaq, 2 weeks ago
Reuters India, 1 month ago
Business Insider, 1 month ago
Reuters India, 2 months ago
Channel NewsAsia, 1 month ago
Yahoo! India, 2 months ago
Yahoo! India, 2 months ago
Stock Nod, 3 months ago
StatNews.com, 2 months ago
Finchannel.com

DAIICHI SANKYO : Researchers at Daiichi Sankyo Release New Data on Immunoglobulins (Suppression of Methionine Oxidation of a Pharmaceutical Antibody Stored in a...

Researchers at Daiichi Sankyo Release New Data on Immunoglobulins (Suppression of Methionine Oxidation of a Pharmaceutical Antibody Stored in a Polymer-Based Syringe) By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data ...
 4 Traders3 weeks ago UCB's Vimpat Approved in Japan for Partial Onset Seizures  Yahoo! Singapore3 weeks ago Japanese MHLW approves lacosamide as adjunctive therapy to treat partial-onset seizures in patients with epilepsy  PharmaBiz3 weeks ago UCB and Daiichi Sankyo will jointly commercialize lacosamide in Japan  Finchannel.com3 weeks ago
[x]  
Nasdaq

Amgen, Daiichi Sankyo team up for biosimilars in Japan

Amgenis on the cusp of getting its first biosimilar approved in the U.S., a knockoff of arthritis fighter Humira, having this week won unanimous support from an FDA advisory committee. When it comes time to take the drug to Japan, the drugmaker will ...
 FiercePharma2 weeks ago Amgen partners with Daiichi on biosimilars after positive FDA panel  FierceBiotech2 weeks ago Amgen and Daiichi Sankyo Team Up for Biosimilars in Japan  Yahoo! Finance2 weeks ago
[x]  

DAIICHI SANKYO : Japan Research Foundation for Clinical Pharmacology 9th Annual Clinical Pharmacology Research Award

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Executive Officer, Vice ...
 4 Traders1 month ago 2016 Japan Pharma Outlook - growth drivers of 12 major Japanese biopharma companies  Before It's News1 month ago Five researchers win Japan Research Foundation for Clinical Pharmacology Research Award  PharmaBiz1 month ago

BRIEF-Daiichi Sankyo plans 5th&6th series unsecured corporate bonds worth total 100 bln yen

July 15 Daiichi Sankyo Co Ltd : * Says it plans to issue 5th series unsecured corporate bonds worth 75 billion yen, with coupon rate of 0.810 percent and maturity date on July 25, 2036 * Says it plans to issue 6th series unsecured corporate ...
 Reuters UK1 week ago BRIEF-Daiichi Sankyo plans 28 mln shares repurchase  Reuters UK1 month ago BRIEF-Daiichi Sankyo to buy back up to 50 bln yen of stock  Reuters UK1 month ago

UCB, Daiichi Sankyo receive Japanese approval for additional indication of lacosamide

Singapore: Daiichi Sankyo Company Limited and Brussels' UCB Biopharma SPRL has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for lacosamide (brand name VIMPAT) as an adjunctive therapy in the treatment ...
 Bio Spectrum Asia3 weeks ago Regeneron-Sanofi's Praluent gets Japan MHLW nod  FiercePharma3 weeks ago
Pharmafile

UCB scores Japanese approval for seizure therapy, Vimpat

UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in the treatment of partial onset seizures in adult patients with epilepsy in Japan. Vimpat is approved in this ...
 Pharmafile3 weeks ago BRIEF-UCBs Vimpat gets Japanese approval  Reuters UK3 weeks ago

New and Generic Drug Approvals: Welchol

Drug Name(s) WELCHOL FDA Application No. (NDA) 021176 Active Ingredient(s) COLESEVELAM HYDROCHLORIDE Company DAIICHI SANKYO Original Approval or Tentative Approval Date May 26, 2000 Chemical Type 1New molecular entity (NME) Review ...
 U.S. Food and Drug Administration1 week ago

DAIICHI SANKYO : Announces Details of Executive Share Options

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Executive Officer, Vice ...
 4 Traders3 weeks ago DAIICHI SANKYO : to Issue Share Options as Remuneration  4 Traders1 month ago

DAIICHI SANKYO : 14th Takamine Memorial Daiichi Sankyo Prize Winner Announced

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Executive Officer, Vice ...
 4 Traders3 weeks ago DAIICHI SANKYO : FTSE Russell Corporation Selects Daiichi Sankyo for FTSE4Good Global Index  4 Traders4 weeks ago FTSE Russell Corporation Selects Daiichi Sankyo for FTSE4Good Global Index  FirstWord Pharma4 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - daiichi sankyo company
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less